Q/C Technologies, Inc. (QCLS) shareholders
Close on Nov 17, 2026Market cap $2.74MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| PharmaCyte Biotech, Inc. | 8,475,368 | 74.00% | 13D (active) amendment | Nov 14, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of QCLS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Quinn Opportunity Partners LLC | 123,024 | 1.50% | $479.79K | −88,366 | 0.02% |
| Vanguard Capital Management LLC | 115,031 | 1.40% | $448.62K | +77,520 | 0.00% |
| Jane Street Group, LLC | 87,241 | 1.07% | $340.24K | −38,947 | 0.00% |
| Geode Capital Management, LLC | 70,682 | 0.86% | $275.66K | +23,292 | 0.00% |
| UBS Group AG | 58,894 | 0.72% | $229.69K | −19,095 | 0.00% |
| Balyasny Asset Management L.P. | 57,692 | 0.70% | $225.00K | New | 0.00% |
| Hrt Financial LP | 50,373 | 0.62% | $196.00K | +27,969 | 0.00% |
| ADAR1 Capital Management, LLC | 50,000 | 0.61% | $195.00K | – | 0.01% |
| Vanguard Fiduciary Trust Co | 43,053 | 0.53% | $167.91K | +27,498 | 0.00% |
| State Street Corp | 25,305 | 0.31% | $98.69K | +12,400 | 0.00% |
| Dimensional Fund Advisors LP | 19,058 | 0.23% | $74.33K | – | 0.00% |
| Northern Trust Corp | 17,997 | 0.22% | $70.19K | New | 0.00% |
| Peak6 LLC | 12,778 | 0.16% | $49.83K | New | 0.00% |
| Pin Oak Investment Advisors Inc | 3,500 | 0.04% | $14.00K | – | 0.01% |
| Tower Research Capital LLC (TRC) | 1,043 | 0.01% | $4.07K | −550 | 0.00% |
| Barclays PLC | 950 | 0.01% | $3.71K | New | 0.00% |
| SBI Securities Co., Ltd. | 100 | 0.00% | $390 | New | 0.00% |
| BlackRock, Inc. | 19 | 0.00% | $74 | – | 0.00% |
| Caitong International Asset Management Co., Ltd | 9 | 0.00% | $35 | New | 0.00% |
| Jones Financial Companies Lllp | 2 | 0.00% | $7 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 21 | 1M | 9.0% | 6 / 5 | 4 / 2 | 0M | 0M |
| Q1 2026 | 18 | 1M | 7.7% | 7 / 5 | 1 / 7 | 0M | 0M |
| Q4 2025 | 19 | 1M | 9.2% | 10 / 2 | 1 / 2 | 1M | 0M |
| Q3 2025 | 11 | 0M | 0.2% | 11 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
10 funds held QCLS in Q2 2026, 71% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of QCLS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 115,031 | 1.40% | $448.62K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 23,353 | 0.29% | $102.05K | 0.00% | May 31, 2026 |
| U.S. Small Cap Portfolio | 13,189 | 0.16% | $34.42K | 0.00% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 6,046 | 0.07% | $26.42K | 0.00% | May 31, 2026 |
| Dimensional U.S. Small Cap ETF | 5,569 | 0.07% | $14.54K | 0.00% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 5,239 | 0.06% | $22.89K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 2,941 | 0.04% | $12.85K | 0.00% | May 31, 2026 |
| Dimensional US Core Equity 1 ETF | 300 | 0.00% | $783 | 0.00% | Jul 31, 2026 |
| Total Stock Market Index Trust | 194 | 0.00% | $757 | 0.00% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -2,400 | -0.03% | -$9.36K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Joshua Silverman | Executive Chairman, Director | 116,835 | 1.43% | Oct 2, 2026 |
| Mitchell Glass | Chief Medical Officer, Director | 12,500 | 0.15% | Apr 15, 2026 |
| Yossef Ehrlichman | Chief Technology Officer | – | – | Sep 22, 2026 |
| Charles Todd Fagan | Chief Financial Officer | – | – | Aug 17, 2026 |
| Ian Thomas Rhodes | Interim CFO | – | – | Apr 18, 2025 |
| Chelsea Sierra Voss | Director | 301,455 | 3.68% | May 14, 2026 |
| Stephen Friscia | Director | 25,000 | 0.31% | Apr 15, 2026 |
| Billy Joe White | Director | 25,024 | 0.31% | Apr 15, 2026 |
| Bruce Bernstein | Director | 25,023 | 0.31% | Apr 15, 2026 |
| PharmaCyte Biotech, Inc. | 10% owner | – | – | Nov 18, 2025 |
| Gary M. Rauch | – | 12,500 | 0.15% | Nov 14, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Joshua Silverman Executive Chairman, Director | Oct 1, 2026 | Award | +77,390 | – | – | 210,845 |
| Joshua Silverman Executive Chairman, Director | Jul 10, 2026 | Award | +16,620 | – | – | 133,455 |
| Joshua Silverman Executive Chairman, Director | Apr 13, 2026 | Award | +16,806 | – | – | 116,835 |
| Joshua Silverman Executive Chairman, Director | Apr 13, 2026 | Award | +162,162 | – | – | 262,191 |
| Chelsea Sierra Voss Director | Mar 30, 2026 | Buy | +1,753 | $3.15 | $5.52K | 61,555 |
| Chelsea Sierra Voss Director | Jan 16, 2026 | Award | +212,500 | – | – | 214,900 |
| Chelsea Sierra Voss Director | Jan 16, 2026 | Award | +25,000 | – | – | 239,900 |
| Billy Joe White Director | Nov 14, 2025 | Award | +22,839 | – | – | 25,024 |
| Mitchell Glass Director, Chief Medical Off. | Nov 14, 2025 | Award | +11,420 | – | – | 12,500 |
| Stephen Friscia Director | Nov 14, 2025 | Award | +22,839 | – | – | 25,000 |
| Joshua Silverman Executive Chairman, Director | Nov 14, 2025 | Award | +91,356 | – | – | 100,029 |
| Bruce Bernstein Director | Nov 14, 2025 | Award | +25,000 | – | – | 25,000 |
| Gary M. Rauch – | Nov 14, 2025 | Award | +11,420 | – | – | 12,500 |
| Mitchell Glass Director, Chief Medical Off. | Oct 3, 2025 | Award | +1,080 | – | – | 1,080 |
| Joshua Silverman Executive Chairman, Director | Oct 3, 2025 | Award | +8,644 | – | – | 8,673 |
| Stephen Friscia Director | Oct 3, 2025 | Award | +2,161 | – | – | 2,161 |
| Gary M. Rauch – | Oct 3, 2025 | Award | +1,080 | – | – | 1,080 |
| Billy Joe White Director | Oct 3, 2025 | Award | +2,161 | – | – | 2,185 |
| Paul Rivard Chief Legal Officer | Aug 24, 2023 | Buy | +150,000 | $1.11 | $166.50K | 400,000 |
| Paul Rivard Chief Legal Officer | Aug 17, 2023 | Buy | +25,000 | $1.12 | $28.00K | 250,000 |
| Paul Rivard EVP of Operations, GC | Dec 8, 2022 | Buy | +10,000 | $1.53 | $15.30K | 225,000 |
| Joshua Silverman Director | Nov 26, 2021 | Buy | +5,000 | $7.55 | $37.75K | 88,775 |
| Joshua Silverman Director | Nov 24, 2021 | Buy | +6,734 | $6.30 | $42.42K | 80,509 |
| Joshua Silverman Director | Nov 24, 2021 | Buy | +3,266 | $7.09 | $23.16K | 83,775 |
| Paul Rivard EVP of Operations, GC | Nov 23, 2021 | Buy | +15,000 | $6.03 | $90.45K | 215,000 |
| Christopher C. Schreiber Director | Apr 16, 2021 | Tax withholding | −46,113 | $4.94 | $227.80K | 88,238 |
| Christopher C. Schreiber Director | Apr 16, 2021 | Option exercise | +131,750 | – | – | 134,351 |
| Christopher C. Chapman JR President, Chief Med. Officer, Director | Apr 16, 2021 | Award | +96,475 | – | – | 96,475 |
| Robert C. Schroeder Director | Apr 16, 2021 | Tax withholding | −14,694 | $4.94 | $72.59K | 29,236 |
| Robert C. Schroeder Director | Apr 16, 2021 | Option exercise | +43,930 | – | – | 43,930 |
| Billy Joe White Director | Apr 16, 2021 | Tax withholding | −38,325 | $4.94 | $189.33K | 71,175 |
| Billy Joe White Director | Apr 16, 2021 | Option exercise | +109,500 | – | – | 112,101 |
| Joshua Silverman Director | Apr 16, 2021 | Option exercise | +109,500 | – | – | 112,101 |
| Joshua Silverman Director | Apr 16, 2021 | Tax withholding | −38,325 | $4.94 | $189.33K | 71,175 |
| Sander Gerber 10% owner | Feb 28, 2020 | Sale | −638 | $2.81 | $1.79K | 240,305 |
| Bay Capital Management LP Hudson 10% owner | Feb 27, 2020 | Sale | −15,300 | $2.72 | $41.62K | 240,943 |
| Bay Capital Management LP Hudson 10% owner | Feb 25, 2020 | Sale | −13,000 | $2.92 | $37.96K | 256,243 |
| Joshua Silverman Director | Jan 1, 2020 | Option exercise | +5,201 | – | – | 5,201 |
| Christopher C. Schreiber Executive Chairman, Director | Jan 1, 2020 | Option exercise | +5,201 | – | – | 5,201 |
| Billy Joe White Director | Jan 1, 2020 | Option exercise | +5,201 | – | – | 5,201 |
| Bay Capital Management LP Hudson 10% owner | Dec 20, 2019 | Buy | +8,000 | $3.02 | $24.16K | 269,243 |
| Bay Capital Management LP Hudson 10% owner | Dec 19, 2019 | Buy | +2,700 | $3.08 | $8.32K | 261,243 |
| Bay Capital Management LP Hudson 10% owner | Dec 18, 2019 | Buy | +7,500 | $3.07 | $23.03K | 258,043 |
| Bay Capital Management LP Hudson 10% owner | Dec 17, 2019 | Buy | +3,000 | $3.03 | $9.09K | 251,043 |
| Bay Capital Management LP Hudson 10% owner | Dec 16, 2019 | Buy | +5,000 | $3.07 | $15.35K | 248,043 |
| Bay Capital Management LP Hudson 10% owner | Dec 13, 2019 | Buy | +6,000 | $3.02 | $18.12K | 243,043 |
| Bay Capital Management LP Hudson 10% owner | Dec 12, 2019 | Buy | +20,600 | $2.98 | $61.39K | 237,043 |
| Bay Capital Management LP Hudson 10% owner | Dec 11, 2019 | Buy | +6,019 | $3.05 | $18.36K | 216,443 |
| Bay Capital Management LP Hudson 10% owner | Dec 11, 2019 | Buy | +26,406 | $3.10 | $81.86K | 210,424 |
| Bay Capital Management LP Hudson 10% owner | Dec 10, 2019 | Buy | +30,000 | $2.97 | $89.10K | 184,018 |
| Bay Capital Management LP Hudson 10% owner | Dec 9, 2019 | Buy | +19,353 | $2.96 | $57.28K | 104,018 |
| Bay Capital Management LP Hudson 10% owner | Dec 9, 2019 | Buy | +50,000 | $2.99 | $149.50K | 154,018 |
| Howard Yeaton CEO, CFO | Oct 2, 2019 | Award | +3,750 | $0.42 | $1.58K | 45,000 |
| Howard Yeaton CEO, CFO | Aug 30, 2019 | Award | +3,750 | $0.43 | $1.61K | 41,250 |
| Howard Yeaton CEO, CFO | Jul 31, 2019 | Award | +3,750 | $0.42 | $1.58K | 37,500 |
| Howard Yeaton CEO, CFO | Jun 28, 2019 | Award | +3,750 | $0.45 | $1.69K | 33,750 |
| Howard Yeaton CEO, CFO | May 24, 2019 | Award | +7,500 | $0.65 | $4.88K | 30,000 |
| Howard Yeaton CEO, CFO | Mar 29, 2019 | Award | +15,000 | $0.97 | $14.55K | 22,500 |
| Howard Yeaton CEO, CFO | Dec 28, 2018 | Award | +7,500 | $1.27 | $9.53K | 7,500 |
| John J. Gormally Chief Executive Officer, Director | Oct 17, 2017 | Award | +150,000 | $0.88 | $132.00K | 180,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Q/C Technologies's stock actually held short. Settlement fails (shares not delivered on time) peaked at 662,610 shares on Sep 17, 2026 over the last 90 days.
See a number that looks wrong?